Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Azelastine/budesonide intranasal - Sedor

Next Previous
Drug Profile

Azelastine/budesonide intranasal - Sedor

Alternative Names: Captisol-enabled™ Budesonide + Azelastine nasal spray - Sedor; CDX-313; LGD-313

Latest Information Update: 04 Oct 2017

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CyDex Pharmaceuticals
  • Developer Sedor Pharmaceuticals
  • Class Glucocorticoids; Phthalazines; Pregnenediones; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Histamine H1 receptor antagonists; Mast cell stabilisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Seasonal allergic rhinitis

Most Recent Events

  • 04 Oct 2017 Azelastine/budesonide is still at phase II development stage for Seasonal allergic rhinitis in Canada (Intranasal) (Sedor Pharmaceuticals website, October 2017)
  • 08 Dec 2015 Captisol-enabled™ azelastine/budesonide licensed to RODES Pharmaceuticals in USA
  • 08 Dec 2015 RODES plans a phase I trial for Seasonal allergic rhinitis in USA (Intranasal)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top